Cardiovascular Adverse Events After Anti-BCMA CAR-T (Ide-Cel and Cilta-Cel) for Relapsed/ Refractory Multiple Myeloma

被引：0
|
作者：
Palfi, Stefanie
Koelmeyer, Himara
Alsina, Melissa
Baz, Rachid
Blue, Brandon
Corallo, Salvatore
De Avila, Gabriel
Freeman, Ciara
Grajales-Cruz, Ariel
Harvey, Kristy
Liu, Hien
Nishihori, Taiga
Oliveira, Guilherme
Oswald, Laura
Puglianini, Omar Castaneda
Shain, Kenneth
Wettenstein, Zachary
Jain, Michael
Locke, Frederick
Alomar, Mohammed
Hansen, Doris
Lee, Dae Hyun
机构：
来源：
CIRCULATION | 2024年 / 150卷
关键词：
D O I：
10.1161/circ.150.suppl_1.4114505
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4114505
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents
    Cohen, Adam D.
    Mateos, Maria-Victoria
    Cohen, Yael C.
    Rodriguez-Otero, Paula
    Paiva, Bruno
    van de Donk, Niels W. C. J.
    Martin, Thomas
    Suvannasankha, Attaya
    De Braganca, Kevin C.
    Corsale, Christina
    Schecter, Jordan M.
    Varsos, Helen
    Deraedt, William
    Wang, Liwei
    Vogel, Martin
    Roccia, Tito
    Xu, Xiaoying
    Mistry, Pankaj
    Zudaire, Enrique
    Akram, Muhammad
    Nesheiwat, Tonia
    Pacaud, Lida
    Avivi, Irit
    San-Miguel, Jesus
    BLOOD, 2023, 141 (03) : 219 - 230
  • [32] Idecabtagene Vicleucel (ide-cel, bb2121), A BCMA-Directed Car T cell therapy, in patients with Relapsed and Refractory Multiple Myeloma (RRMM): Initial KarMMa results
    Einsele, H.
    Weisel, K.
    Goldschmidt, H.
    Munshi, N. C.
    Anderson, L. D., Jr.
    Shah, N.
    Jagannath, S.
    Berdeja, J.
    Lonial, S.
    Raje, N.
    Siegel, D. S.
    Lin, Y.
    Oriol, A.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    San Miguel, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 90 - 91
  • [33] Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-Cell therapy, in patients with relapsed and refractory multiple myeloma: Updated KarMMa results
    Einsele, H.
    Oriol, A.
    San-Miguel, J.
    Kansagra, A.
    Madduri, D.
    Shah, N.
    Moreau, P.
    Yakoub-Agha, I
    Delforge, M.
    Cavo, M.
    Goldschmidt, H.
    Weisel, K.
    Rambaldi, A.
    Reece, D.
    Rodriguez-Otero, P.
    Petrocca, F.
    Connarn, J. N.
    Patel, P.
    Huang, L.
    Campbell, T. B.
    Hege, K.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 120 - 121
  • [34] Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series
    Attar, Narsis
    Cirstea, Diana
    Branagan, Andrew R.
    Yee, Andrew J.
    Frigault, Matthew J.
    Raje, Noopur
    BLOOD, 2023, 142
  • [35] A model to predict the risk of prolonged thrombocytopenia recovery in relapsed/refractory multiple myeloma patients after anti-BCMA CAR-T treatment
    Li, Chunrui
    Wang, Di
    Fang, Baijun
    Huang, He
    Li, Jianyong
    Chen, Bing
    Liu, Jing
    Ren, Hanyun
    Dong, Yujun
    Hu, Kai
    Liu, Peng
    Zhang, Xi
    Mi, Jian-Qing
    Li, Zhenyu
    Ding, Kaiyang
    Cai, Song-Bai
    Gui, Hong-Yu
    Wang, Wen
    Qiu, Lugui
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S195 - S196
  • [36] Use of cilta-cel CAR T cells following previous use of a BCMA-directed CAR T-cell product in heavily treated patients with relapsed/refractory multiple myeloma: a single institution case series
    Attar, Narsis
    Cirstea, Diana
    Branagan, Andrew
    Yee, Andrew
    Frigault, Matthew
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S161 - S161
  • [37] Correlative analysis to define patient profiles associated with manufacturing and clinical endpoints in relapsed/refractory multiple myeloma (RRMM) patients treated with idecabtagene vicleucel (ide-cel; bb2121), an anti-BCMA CAR T cell therapy.
    Rytlewski, Julie
    Fuller, Jaymes
    Mertz, David R.
    Freeman, Ciara
    Manier, Salomon
    Shah, Nina
    Campbell, Timothy Brandon
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Safety and efficacy of standard of care ciltacabtagene autoleucel (Cilta-cel) for relapsed/refractory multiple myeloma (RRMM): real world experience
    Sidana, Surbhi
    Patel, Krina
    Peres, Lauren
    Bansal, Radhika
    Kocoglu, M. Hakan
    Shune, Leyla
    Atrash, Shebli
    Smith, Kinaya
    Ferreri, Christopher
    Dhakal, Binod
    Chhabra, Saurabh
    Parrondo, Ricardo
    Costello, Patrick
    Midha, Shonali
    Martin, Thomas
    Simmons, Gary
    Alsina, Melissa
    Htut, Myo
    Voorhees, Peter
    Sborov, Douglas
    Khouri, Jack
    Wong, Sandy
    Janakiram, Murali
    Lin, Yi
    Hansen, Doris
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S61 - S62
  • [39] Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting bispecific antibody treatment
    San-Miguel, Jesus
    Mateos, Maria-Victoria
    Cohen, Yael C.
    Rodriguez-Otero, Paula
    Paiva, Bruno
    van de Donk, Niels W. C. J.
    Martin, Thomas
    Abu-Zaid, Mohammad
    Corsale, Christina
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Varsos, Helen
    Deraedt, William
    Wang, Liwei
    Roccia, Tito
    Li, Claire
    Mistry, Pankaj
    Xu, Xiaoying
    Zudaire, Enrique
    Akram, Muhammad
    Nesheiwat, Tonia
    Pacaud, Lida
    Avivi, Irit
    Cohen, Adam D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S35 - S36
  • [40] Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature
    Guoxing Zhao
    Runhong Wei
    Lei Feng
    Yi Wu
    Feng He
    Mingxing Xiao
    Zhi Cheng
    Cancer Immunology, Immunotherapy, 2022, 71 : 39 - 44
12345